2013 - China antineoplastic industry trends and investment advisory report 2017

Trends and investment advisory report China 2017 ----------------------------------- antineoplastic industry - 2013 --------------------------------- [Report No. No.] 23010 [release date] in August 2013 [Delivery way] EMIL electronic version or EMS [Report format] [Paper version]: 6500 yuan [Electronic version]: 6800 yuan [paper + electronic]: 7000 yuan (price discount) [telephone] 010-57101528 [Customer Order QQ] 1032751828, 183319016, 24 hours: 13366389949 [contact] Status [source connected to the high Lu Juan] http://www.szzyjjyjy.com/a/huaxueyao/14140.html (Click to see main text) Operation of the first part of the industry Chapter 1 Overview Section antitumor industry sector definitions antineoplastic 1 I. Definition of two anticancer drugs, antineoplastic agents Application 4 Section 6 a antineoplastic industry overview, industry development of the global anti-tumor Overview 6 II anticancer status of the domestic industry set forth in section III anticancer 13 R & D Status and trends 27 I. Overview of the development of anticancer drugs 27 Second, the natural (herbal) antineoplastic assay development 28 Chapter 2012- 2017 China market size anticancer industry analysis 30 Section 2012--2017 anticancer industry market scale of China's analysis of 30 Section 2012--2017 basic characteristics of China's anticancer industry analysis III 2012- 2017 39 Chinese antineoplastic industry sales revenue of 44 fourth 2012--2017 China's anticancer industry market concentration analysis of 52 V 2012--2017 China's industry market share analysis anticancer 2013- 2017 55 Section VI China anticancer industry market size forecast 60 Chapter Chinese antineoplastic chain structure analysis of 67 Section 67 Chinese antineoplastic a chain structure, industry chain before 67 II features 68 Section II China antineoplastic industry Development Trend of a chain 69, chain life cycle analysis 69 Second, the value chain flow analysis 71 Third, the evolution path and trends 74 Section Chinese antineoplastic chain competitive analysis Chapter 79 China regional market analysis anticancer industry 93 Section 2012 North China anticancer industry analysis 93 I. Development Status 2012 industry analysis 93 Second, in 2012 the market size analysis 95 Third, 2012--2017 market demand analysis 98 Fourth, 2013--2017 years of industry Development prospects of the northeastern region 102 Section 2012 antineoplastic industry analysis 107 First, in 2012 the industry status quo analysis 107 Second, in 2012 the market size analysis 111 Third, 2012--2017 Market demand analysis of 114 Fourth, 2013- 2017 industry forecast 117 Section 2012 East antineoplastic industry analysis on development of a 118, in 2012 industry analysis 118 Second, in 2012 the market size analysis 120 Third, 2012--2017 market demand analysis 122 four , 2013--2017 125 years of industry development prospects of the fourth quarter 2012 in southern China Industry Analysis on Development of anticancer 130 a 2012 industry analysis 130 Second, in 2012 the market size analysis 132 Third, 2012--2017 years of market demand analysis 133 Fourth, 2013--2017 years of industry development forecast 2012 Love 137 V in a region 140 anticancer industry analysis, in 2012 the industry status quo analysis 140 Second, in 2012 the market size analysis 142 Third, 2012- 2017 market demand analysis 147 Fourth, 2013--2017 years of industry development prospects of the Southwest anticancer Industry Analysis VI 2012 147 150 a development situation, in 2012 industry analysis 150 Second, in 2012 the market size analysis 152 Third, 2012 --2017 market demand analysis 154 Fourth, 2013--2017 155 years of industry development forecast VII 2012 Northwest antineoplastic industry analysis on development of a 157, 157 two 2012 industry analysis, 2012 - 2017 market demand analysis 158 Third, 2013--2017 years of industry development prospects of China 159 Chapter antineoplastic manufacturing cost analysis 161 Section 2012--2017 年 antineoplastic manufacturing a product cost of sales analysis 161, 2012 - 2017 Industry Sales total cost analysis 161 Second, comparative analysis of different scale enterprises in cost of sales 162 Third, the comparative analysis of different ownership cost of sales 164 Section 2012--2017 年 antineoplastic manufacturing industry sales cost analysis 165 a, 2012 - 2017 industry sales expenses Analysis of total 165 Second, comparative analysis of different scale enterprises selling expenses 166 Third, the comparative analysis of different ownership enterprises selling expenses 166 Section 2012--2017 年 antineoplastic manufacturing industry management cost analysis 167 a, 2012 - 2017 managing the total cost of industry analysis 167 Second, the different sizes of enterprise management cost comparison analysis 167 Third, the comparative analysis of different ownership management fees 168 IV 2012--2017 年 antineoplastic 168 manufacturing industries a financial cost analysis, 2012 - total financial expenses 168 two 2017 Industry Analysis Comparative analysis of different scale enterprises financial expenses 169 Third, different ownership comparative analysis of financial expenses 169 Chapter 170 Section Chinese antineoplastic market demand 2012--2017 年 antineoplastic 170 a productivity analysis, in 2011 China antineoplastic Capacity 170 Second, in 2012 three Chinese anti-tumor capacity of 170, 2012 - 2017 Chinese anti-tumor capacity utilization analysis 170 Section 2012--2017 年 antineoplastic yield analysis 171 First, the domestic market potential of 171 Second, opportunities Challenges bring about change analysis 173 Third, 2012--2017 Section 174 of China's anti-tumor growth 2012--2017 年 antineoplastic demand a 175, 2012 - 2017 Chinese antineoplastic market supply analysis 175 Second, 2013-2017 In China market demand forecast 177 anticancer drugs associated with the second part of Chapter VII of the 2012 market analysis - Comprehensive analysis of the relevant industry sector in 2017 antineoplastic market run 180 Section 2012 - 2017 antineoplastic run upstream industry analysis 180 a upstream antineoplastic industry introduced 180 Second, the analysis anticancer industry upstream development of 183 three anticancer drugs industry upstream industry influence analysis for anticancer drugs 199 Section 2012--2017 年 antineoplastic industry downstream operation analysis 199 a , antineoplastic downstream industry introduced 199 Second, the analysis downstream industry development status anticancer 199 Third, antineoplastic industry downstream industry analysis of the impact of anticancer 206 Part III Chapter VIII of Chinese market research analysis antineoplastic price analysis Section 209 anticancer Chinese calendar Price Review Section 209 Chinese antineoplastic 209 a current market price, the current price of the product analysis 209 Second, the product price forecast future Section 210 Chinese antineoplastic Price Influencing Factors 210 a the global economic crisis has affected 210 Second, the RMB exchange rate changes affect 215 Third, other antineoplastic 218 Chapter IX China Import and Export Analysis Section 219 Section 219 anticancer drugs in recent years, China's import and export profiles antineoplastic total import and export industry calendar Section 222 cases the amount of import and export situation of Chinese industry outlook antineoplastic 222 First, the main influencing factors of China's import and export analysis 222 two antineoplastic, 2012 - 2017 Chinese imports of antineoplastic industry trend outlook 225 Third, 2012-2017 China's export situation outlook antineoplastic industry market competition analysis 227 Part IV Chapter anticancer industry competition analysis Section 228 anticancer industry concentration analysis 228 First, the anticancer market concentration analysis 228 II. antineoplastic corporate concentration analysis 228 Third, the regional concentration analysis 228 antineoplastic antitumor industry competition analysis Section 229 a 2012 competitive analysis 229 Second, the 2012 competition and foreign anticancer product anticancer industry analysis 230 Third, the 2012 analysis of 275 domestic and foreign competition antineoplastic IV 2012 antineoplastic market competition analysis of 276 V, 2012 analysis of market concentration anticancer 277 six, 2012 - 2017 major domestic antineoplastic Enterprise Trends Chapter XI 278 key enterprises operating conditions analysis 280 Jiangsu Hengrui Medicine Section 280 a, 280 two company's main business, the company operating status 281 Third, the company advantages and disadvantages of Section 284 shares of Shenzhen Accord Pharmaceutical Co., 288 a company, the company's main business 288 Second, the company operating conditions three 289, 2012 - 2017 Development Prospects 292 Section 294 of Zhejiang Hisun a company's main business 294 Second, the company operating conditions 295 IV Jiangsu Stockhausen medicine 297 a, 297 two company's main business, the company operating status 298 Third, 2012--2017 development prospects of the company 299 300 V a harbinger Pharmaceutical Co., Ltd., the company's main business 300 Second, the company three operating conditions of 302, 2012 - 2017 the company's development prospects and trends 303 Part V Investment Analysis Chapter XII 2013--2017 China's anticancer industry forecast analysis 307 Section 2013--2017 antineoplastic Industry of China 307 a macro forecast, 2013--2017 antineoplastic industry macro forecast of China 307 Second, 2013--2017 antineoplastic industrial development prospects of China's 312 Third, China's development of anticancer Industry Forecast and Analysis Section 312 2013- 2017 Chinese antineoplastic market situation analysis 313 a 2013 - 2017 antineoplastic production situation analysis and forecast China 313 Second, the factors anticancer Chinese market operation Impact Analysis 314 Section 2013--2017 antineoplastic market trend analysis of China 314 First, 2008--2012 summary of China's market trends antineoplastic 314 Second, the anti-tumor drug market monopoly 315 Third, 2013 - China Development Trend of antineoplastic 2017 317 Fourth, 2013--2017 antineoplastic market of China Space 319 V. 2013--2017 antineoplastic industrial policy trends of China 320 Chapter XIII of 2013 - Section 322 Status anticancer investment risk and investment strategies of the Chinese antitumor industry a 2017 analysis of 322, 2011-2012 The overall structure of investment and 322 Second, 2011--2012 investment scale of the case 325 Third, 2011--2012 investment growth in the case of 327 Fourth, 2011--2012 Year Industry Investment Analysis 328 Section 329 anticancer benefit analysis of investment industry a , 2011--2012 Analysis 329 two anticancer industry investment situation in 2013 - 2017 antineoplastic 332 three-benefit analysis of investment industry in 2013 - 2017 forecast antineoplastic Trends for 333 four 2013 - 2017 antineoplastic investment industry direction 336 five 2013 - 2017 347 recommendations antineoplastic industry investment report Charts Chart: 2007 "New Pharmacology" (16th edition) incorporation of antineoplastic 3 Chart: 2008--2012 Global antineoplastic market size and growth 12 Chart: 2011 global pharmaceutical giant famous antineoplastic sales 12 Chart: Chinese Cancer prevalence 21 Charts: 22 Chinese cities tumor prevalence chart: Cancer prevalence in rural China 22 Chart: China resident neoplastic disease two weeks outpatient visit rate 23 Chart: Chinese urban residents tumor disease two weeks outpatient visit rate 24 Chart: Chinese rural residents tumor disease two weeks outpatient visit rate 24 chart: the top ten overall cancer mortality 25 Charts: Top Ten cancer mortality (by male points) Chart 26: the top ten cancer mortality (by female points) Chart 26: the top ten cancer mortality (by city points) Chart 26: the top ten cancer mortality ( by rural points) Chart 27: 2008 - 2012 antineoplastic market size and growth 60 Chart: 2013--2017 年 61 antineoplastic market size forecast Chart: industry lifecycle judgment 71 Chart: 2012 North China chemical raw medicine Output and Growth 95 Chart: 2012 North China Chinese medicine production and growth 95 Chart: 2012 Northeast China chemical raw medicine production and growth 111 Chart: 2012 Northeast China Chinese medicine production and growth 111 Chart: 2010--2050 World Cancer morbidity and mortality prediction 115 Chart: 2007 top ten global anticancer drugs sales statistics chart 116: 2003 - 2010 global market growth antineoplastic Statistics 116 Chart: 2003 - 2007 global sales of the eight antineoplastic business anticancer drugs Amount 117 Chart: 2012 East chemical raw medicine production and growth 119 Chart: 2012 East Chinese medicine production and an increase of 120 Chart: 2012 South China chemical raw medicine production and increase of 131 Chart: 2012 South China medicine Output and Growth Chart 132: 2012 Love regions original chemical production and growth 142 Chart: 2012 Years of Chinese medicine production and growth in the region 142 Chart: China's major high incidence of cancer statistics analysis 147 chart: Sichuan "; five"; during the Statistical analysis of the pharmaceutical industry, industrial output 151 Chart: Sichuan "; five"; during the statistical analysis of the pharmaceutical industry taxes 151 Chart: 2012 Southwest China chemical raw medicine production and growth 152 Chart: 2012 Southwest Region medicine production and growth Chart 152: 2012 Northwest original chemical production and growth 158 Chart: 2012 Northwest 158 ??Chinese medicine production and growth charts: 2011--2012 年 original drug chemical manufacturing industry output value and sales growth (including anticancer) 161 Chart: 2011--2012 年 original drug manufacturing chemicals and main business revenue growth (including anticancer) Chart 161: 2011--2012 年 original drug chemical manufacturing main business costs and growth (including anticancer) 162 chart: 2012 original drug chemical manufacturing companies of all sizes industrial sales output value and growth (including anticancer) 162 chart: 2012 The original chemical-manufacturing companies of all sizes and main business revenue growth (including anticancer) 163 chart: 2012 In the original drug chemical manufacturing enterprises of different sizes main business costs and growth (including anticancer) 163 chart: 2012 manufacturer of chemical raw medicine industrial sales output value of enterprises of different ownership and growth (including anticancer) 164 chart: 2012 The original drug chemical manufacturing enterprises of different ownership and main business revenue growth (including anticancer) 164 chart: 2012 The original chemical-manufacturing enterprises of different ownership and growth of the main business costs (including anticancer) 165 chart: 2011- 2012 manufacture and sale of chemical raw drug costs and growth (including anticancer) 165 chart: 2012 The original drug manufacturing chemicals businesses of all sizes cost of sales and growth (including anticancer) 166 chart: 2012 manufacturer of chemical raw medicines enterprises of different ownership and increase the cost of sales (including anticancer) Chart 166: 2011--2012 年 original drug manufacturing chemicals management fees and growth (including anticancer) 167 chart: 2012 The original chemical-manufacturing companies of all sizes and administrative expenses and growth (including anticancer) 167 chart: 2012 The original chemical-manufacturing enterprises of different ownership and increase administrative expenses (including anticancer) Chart 168: 2011--2012 年 manufacture of chemical raw medicines and increase the financial costs (including anti- oncology) 168 chart: 2012 manufacturer of chemical raw medicine enterprises of different sizes and increase financial expenses (including anticancer) 169 chart: 2012 The original chemical-manufacturing enterprises of different ownership and increase financial expenses (including anticancer) 169 Chart: 2008 - 2012 antineoplastic productivity and growth Chart 170: 2008 - 2012 antineoplastic Output and Growth Chart 171: 2013--2017 年 antineoplastic production forecast 172 chart: In 2010 - 2011 the market antineoplastic categories Share Changes Line Chart 178 Chart: 2008--2012 Chinese Patent Output and Growth Chart 182: 2008 - 2012 original chemical production and growth 182 chart: In 2011 10 Month - November 2012 the pharmaceutical industry investment and growth 187 trend chart: In 2011 10 Month - November 2012 than in the case of the pharmaceutical industry investment accounted for 188 chart: In 2010 11 Month - November 2012 the pharmaceutical industry to use foreign investment contract item number and amount of growth charts Chart 189: 2011 11 Month - November 2012 the pharmaceutical industry to use foreign contract projects and the amount accounted for 189 cases chart: In 2011 10 Month - November 2012 190 pharmaceutical lines added value growth rate trend graph: In 2011 10 Month - November 2012 chemicals original drug daily average yield and growth charts 191 chart: In 2011 10 Month - November 2012 original chemical production and growth charts 191 chart: In 2011 10 Month - November 2012 average daily production and medicine 192 chart its growth trend: In 2011 10 Month - November 2012 proprietary yield and growth charts 192 chart: In 2011 10 Month - November 2012 monthly sales value of the pharmaceutical industry and its growth charts 193 chart: October 2011 - November 2012 cumulative sales value of the pharmaceutical industry and its growth charts 193 chart: In 2011 10 Month - November 2012 total retail sales of Chinese and Western medicines and its monthly growth rate trend graph 194: October 2011 - November 2012 total retail sales of Chinese and Western medicines and its cumulative growth charts 194 chart: In 2011 11 Month - November 2012 import and export of pharmaceuticals and their growth charts 196 chart: In 2011 10 Month - November 2012 the pharmaceutical industry single-month export value and growth charts Chart 196: October 2011 --2012 年 November total export value of the pharmaceutical industry and its growth charts 197 chart: In 2011 11 Month - November 2012 PPI pharmaceutical industry 198 chart and CPI trend: In 2011 11 Month - November 2012 Chinese and Western medicines and health care supplies retail price index movements 198 Charts: 2011 - 2012 Cancer Hospital Number 201 chart: 2008-2012 January-July of medical and health institutions Chart number 202: 2008-2012 January to July the number of hospital 203 chart: 2008-2012 January to July the number of primary care health institutions 203 chart: 2008-2012 January to July the number of professional and public health agencies 204 Chart: 2008 - 2012 January-July tertiary hospital chart number 204: 2008-2012 January-July level II hospital chart number 205: 2008-2012 January-July level of 205 hospital chart number: 2008-2012 1- In July the number of public hospitals, 206 Charts: 2008-2012 January to July the number of private hospitals 206 chart: My nine city hospitals antitumor market structure 229 chart: 2011--2012 年 Hengrui Medicine Co., Ltd. 281 Index share analysis chart: 2011--2012 年 Hengrui Medicine Co., Ltd. Analysis of growth capacity index 281 chart: 2011--2012 年 operational capacity index Hengrui Medicine Co., Ltd. 281 Chart Analysis: 2011--2012 年 Hengrui Medicine Co., Ltd. 282 chart analysis of earnings quality indicators : 2011--2012 年 operational capacity index Hengrui Medicine Co., Ltd. Analysis Chart 282: 2011--2012 年 Hengrui Medicine Co., Ltd. Financial Risk Index of 282 Charts: 2011--2012 earnings per share index analysis Hengrui Medicine Co., Ltd. Chart 282: 2011--2012 年 Hengrui Medicine Co., Ltd. net assets Index of 283 Charts: 2011--2012 年 Hengrui Medicine Co., Ltd. net profit 283 Index of Charts: 2011--2012 年 Hengrui Medicine Co., Ltd. Revenue Index Chart Analysis 284: 2011--2012 Uniformly share index analysis Pharmaceutical Co., Ltd. 289 chart: 2011--2012 Uniformly Pharmaceutical Co., Ltd. 289 Growth Index of Charts: 2011--2012 Uniformly profitability Pharmaceutical Co., Ltd. Index of 290 Charts: 2011--2012 Uniformly Pharmaceutical Co., Ltd. earnings quality indicators analyzed 290 charts: 2011--2012 Uniformly Pharmaceutical Co., Ltd. operational Index of 290 Charts: 2011--2012 Uniformly Pharmaceutical Co., Ltd. Finance Risk Analysis 290 index chart: 2011--2012 Uniformly Pharmaceutical Co., Ltd. Balance Sheet 290 Index of Charts: 2011--2012 Uniformly Pharmaceutical Co., Ltd. Income Statement 291 Index of Charts: 2011--2012 Uniformly Pharmaceutical Co. Shares Analysis of the company's earnings per share 291 index chart: 2011--2012 Uniformly Pharmaceutical Co., Ltd. ROE index analysis 291 chart: 2011--2012 年 Hisun Pharmaceutical Co., Ltd. 295 chart indicators share analysis: 2011-2012 Hisun Pharmaceutical Co., Ltd. 295 Growth Index of Charts: 2011--2012 年 Hisun Pharmaceutical Co., Ltd. Profitability Index Chart Analysis 295: 2011--2012 年 Hisun Pharmaceutical Co., Ltd. 296 chart analysis of earnings quality indicators: 2011--2012 年 Hisun Pharmaceutical Co., Ltd. Profitability Index of 296 Charts: 2011--2012 年 Hisun Pharmaceutical Co., Ltd. Financial Risk Index of 296 Charts: 2011--2012 年 Hisun Pharmaceutical Co., Ltd. Balance Sheet Index of 296 Charts: 2011--2012 年 Hisun Pharmaceutical Co., Ltd. Income Statement 296 Index of Charts: 2011--2012 年 Hisun Pharmaceutical Co., Ltd. EPS 297 Index of Charts: 2011--2012 年 Hisun Ltd. ROE Index of 297